<DOC>
	<DOCNO>NCT00385606</DOCNO>
	<brief_summary>The purpose study evaluate tolerability efficacy addition rofecoxib first-line chemotherapy , evaluate efficacy prolong continuous infusion gemcitabine combination cisplatin treatment patient affect advanced non-small cell lung cancer .</brief_summary>
	<brief_title>GECO : Study Rofecoxib Prolonged Constant Infusion Gemcitabine Polychemotherapy Treatment Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The primary end-points GECO study - To evaluate tolerability three innovative schedule treatment advance NSCLC - To evaluate efficacy addition rofecoxib first-line chemotherapy treatment patient affect advanced NSCLC - To evaluate efficacy prolong continuous infusion ( p.c.i . ) gemcitabine , fix infusion rate 10 mg/sqm/minute ) versus standard administration 30 minute , combination cisplatin , treatment patient affect advanced NSCLC Four treatment arm plan . - ARM A standard treatment : cisplatin + gemcitabine - ARM B cisplatin + gemcitabine + rofecoxib - ARM C cisplatin + p.c.i . gemcitabine ( 10 mg/sqm/minute ) - ARM D cisplatin + p.c.i gemcitabine ( 10 mg/sqm/minute ) + rofecoxib The phase II part study experimental arm B , C D conduct evaluate tolerability three treatment arm . The phase III study efficacy design accord factorial 2x2 model plan comparison - The efficacy rofecoxib : A + C ( arm without rofecoxib ) v B+D ( arm rofecoxib ) - The efficacy p.c.i . gemcitabine : A + B ( arm standard infusion gemcitabine ) v C+ D ( arm p.c.i gemcitabine )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<criteria>Cytologic histologic diagnosis nonsmall cell lung cancer Disease stage IIIB IV Age less 70 year ECOG performance status 2 less Patients cerebral metastasis permit asymptomatic require radiation therapy concomitant chemotherapy Negative history allergy nonsteroidal antiinflammatory and/or sulphonamide drug Patients previously treat radiation therapy permit least 4 week pass since last therapy Written inform consent Previous chemotherapy Previous concomitant malignant neoplasm ( exclude adequately treat baso spinocellular skin carcinoma carcinoma situ cervix ) Neutrophil &lt; 2000/mm3 , platelet &lt; 100,000/mm3 , haemoglobin &lt; 10 g/dl Creatinine &gt; 1.25 x upper normal limit GOT and/or GPT and/or Bilirubin &gt; 1.25 upper normal limit absence hepatic metastasis GOT and/or GPT and/or Bilirubin &gt; 2.5 upper normal limit presence hepatic metastasis Any concomitant pathology would , investigator 's opinion , contraindicate use drug study Inability comply followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>prolong continuous infusion</keyword>
	<keyword>Cox-2 inhibitor</keyword>
</DOC>